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OBJECTIVE—Activation of the receptor for advanced glycation
end products (RAGE) in diabetic vasculature is considered to be
a key mediator of atherogenesis. This study examines the effects
of deletion of RAGE on the development of atherosclerosis in the
diabetic apoE
/ model of accelerated atherosclerosis.
RESEARCH DESIGN AND METHODS—ApoE
/ and RAGE
//
apoE
/ double knockout mice were rendered diabetic with
streptozotocin and followed for 20 weeks, at which time plaque
accumulation was assessed by en face analysis.
RESULTS—Although diabetic apoE
/ mice showed increased
plaque accumulation (14.9  1.7%), diabetic RAGE
//apoE
/
mice had signiﬁcantly reduced atherosclerotic plaque area (4.9 
0.4%) to levels not signiﬁcantly different from control apoE
/
mice (4.3  0.4%). These beneﬁcial effects on the vasculature
were associated with attenuation of leukocyte recruitment; de-
creased expression of proinﬂammatory mediators, including the
nuclear factor-B subunit p65, VCAM-1, and MCP-1; and reduced
oxidative stress, as reﬂected by staining for nitrotyrosine and
reduced expression of various NADPH oxidase subunits, gp91phox,
p47phox, and rac-1. Both RAGE and RAGE ligands, including
S100A8/A9, high mobility group box 1 (HMGB1), and the advanced
glycation end product (AGE) carboxymethyllysine were increased
in plaques from diabetic apoE
/ mice. Furthermore, the accumu-
lation of AGEs and other ligands to RAGE was reduced in diabetic
RAGE
//apoE
/ mice.
CONCLUSIONS—This study provides evidence for RAGE play-
ing a central role in the development of accelerated atheroscle-
rosis associated with diabetes. These ﬁndings emphasize the
potential utility of strategies targeting RAGE activation in the
prevention and treatment of diabetic macrovascular complica-
tions. Diabetes 57:2461–2469, 2008
T
he receptor for advanced glycation end products
(RAGE) is a multiligand cell surface molecule
belonging to the immunoglobulin superfamily
(1). It is expressed as full-length, N-truncated,
and C-truncated isoforms, generated in humans by alter-
native splicing (2). Activation of the full-length RAGE
receptor has been implicated in a range of chronic dis-
eases, including various diabetic complications and ath-
erosclerosis (1). In particular, studies in RAGE
/ mice
that carry the dominant-negative form of the receptor
(2–6) and in RAGE-overexpressing mice (7) have con-
ﬁrmed an important role of RAGE activation in the devel-
opment of diabetic nephropathy, neuropathy, and
impaired angiogenesis. RAGE activation has also been
implicated in the acceleration of atherosclerotic lesion
formation as well as in the maintenance of proinﬂamma-
tory and prothrombotic mechanisms, characteristic of
diabetes-accelerated atherosclerosis (8,9). RAGE also rep-
resents an important mediator of oxidative stress in dia-
betes. Activation of RAGE in vitro leads to increased
NADPH oxidase expression, mitochondrial oxidase activ-
ity, and downregulation of endogenous antioxidant activ-
ity (10,11). RAGE
/ mice have a suppression of
neointimal proliferation after externally induced arterial
injury in the absence of diabetes (12). Moreover, blockade
of RAGE-dependent signaling by soluble RAGE (sRAGE)
has been shown to inhibit the progression of atheroscle-
rotic changes (8,9) and kidney disease (3) in diabetic mice,
possibly by suppressing the activation of nuclear factor-B
(NF-B) activation and inﬂammatory cytokine expression.
The present study examined the role of RAGE in the
development of diabetes-accelerated atherosclerosis in a
model of insulin deﬁciency, the streptozotocin-induced
diabetic RAGE
//apoE
/ mouse. Our aim was to deter-
mine the effect of global RAGE deﬁciency, which includes
absence of both the full-length receptor and endogenous
sRAGE on the development of vascular lesions in the
presence and absence of diabetes. Furthermore, key me-
diators of the atherosclerotic process in diabetes were
examined, and the effects on these pathways were as-
sessed in these RAGE-deﬁcient mice.
RESEARCH DESIGN AND METHODS
This study used the well-characterized apoE
/ mouse model of accelerated
atherosclerosis, whereby mice develop complex vascular lesions after 20
weeks of diabetes that resemble the morphology seen in human atheroscle-
rosis (9,13–15). Six-week-old male apoE
/ mice (backcrossed 20 times to a
C57BL/6 background; Animal Resource Centre, Canning Vale, Western Aus-
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//apoE
/ mice, generated by backcrossing RAGE
/ mice
(16) on the C57BL/6 background into apoE
/ mice on the same background
for 10 generations (University of Heidelberg, Heidelberg, Germany) (Supple-
mentary Fig. 1, available in an online appendix at http://dx.doi.org/10.2337/
db07-1808), were housed at the Precinct Animal Centre at Baker Heart
Research Institute and studied according to National Health and Medical
Research Council (NHMRC) guidelines. Mice (n  24/group) were rendered
diabetic via ﬁve daily intraperitoneal injections of 55 mg/kg streptozotocin
(Boehringer, Mannheim, Germany) per day, resulting in insulin deﬁciency
(13). Control animals received vehicle (citrate buffer) alone. All animals were
followed for 20 weeks. Mice were allowed access to standard mouse chow and
water ad libitum. Mice were killed using an intraperitoneal injection of 100
mg/kg Euthal (Delvet, Seven Hills, Australia), followed by exsanguination by
cardiac puncture. Excised aortas (n  10–14) were placed in 10% neutral
buffered formalin and quantitated for lesion area before being embedded in
parafﬁn for immunohistochemical analysis. In the remaining mice (n 
10–14), aortas were snap-frozen in liquid nitrogen and stored at 70°C for
subsequent RNA extraction. At the conclusion of the study, GHb was
measured by high-performance liquid chromatography (17). Total plasma
cholesterol, HDL, and triglyceride concentrations were measured in 9–10
mice per group by autoanalyzer. LDL cholesterol was calculated by the
Friedewald formula. The S100 A8/A9 ELISA kit (Immundiagnostik, Bensheim,
Germany) was used to measure this S100 isoform in plasma according to the
manufacturer’s instructions. A Quantitative ELISA (Shino-Test, Tokyo) was
used to measure plasma high mobility group box 1 (HMGB1) concentration.
Plaque area quantitation. Plaque area was quantitated as described previ-
ously (13,15). In brief, aortas (n  10–14 aortas/group) were cleaned of excess
fat under a dissecting microscope and subsequently stained with Sudan
IV-Herxheimer’s solution (0.5% wt/vol) (Gurr; BDH, Poole, U.K.). Aortas were
dissected longitudinally; divided into arch, thoracic, and abdominal segments;
and pinned ﬂat onto wax. Images were acquired with a dissecting microscope
equipped with an Axiocam camera (Zeiss, Heidelberg, Germany). Total and
segmental plaque area was quantitated as a percentage area of aorta stained
(Adobe Photoshop version 7.0). Tissue was subsequently embedded in paraf-
ﬁn, and sections were cut for immunohistochemical analysis.
Real-time RT-PCR. Total RNA was extracted from whole aorta by homoge-
nizing (Polytron PT-MR2100; Kinematica, Littau-Lucerne, Switzerland) in
TRIzol (Life Technologies, Rockville, MD). Total RNA was then DNase-treated
(DNA removal kit; Ambion, Austin, TX), and cDNA was synthesized by reverse
transcription (Pierce Biotechnology, Rockford, IL). Quantitative real-time
RT-PCR was performed using the Taqman System on an ABI Prism 7500
Sequence Detector (Applied Biosystems, Foster City, CA) and analyzed using
software detection systems (SDS version 1.9) software. Gene expression was
normalized to 18S rRNA (Applied Biosystems). Detailed information on
probes is provided in Supplementary Table 1. For each analysis, 10–14
animals per group were used.
Immunohistochemistry. Serial 4-m sections were stained for -smooth
muscle actin (-SMA) (1:200; DakoCytomation, Carpinteria, CA), the macro-
phage marker F4/80 (1:50; Serotec, Oxford, U.K.), nitrotyrosine (1:50; Chemi-
con, Temecula, CA), S100A8/A9 (1:250; Immundiagnostik), HMGB1 (1:1,000;
Abcam, Cambridge, U.K.), carboxymethyllysine (CML) (1:1,000; Abcam), the
T-cell marker CD3 (1:50; Abcam), collagens III and IV (goat anti-human
collagen III and IV; 1:75 and 1:800, respectively; SouthernBiotech, Birming-
ham, AL), vascular cell adhesion molecule-1 (VCAM-1) (1:50; Pharmingen, San
Diego, CA), and monocyte chemotactic protein-1 (MCP-1) (1:500; R&D Sys-
tems, Minneapolis, MN). Enzymatic trypsin antigen retrieval was used for
F4/80, pepsin digestion in 0.01 mol/l HCl was used for collagen III and IV, and
heat-induced antigen retrieval in 0.01 mol/l citric acid (pH 6.0) was applied for
HMGB1 and CD3 antibodies. Sections were incubated with the primary
antibody overnight at 4°C. Secondary antibody, biotinylated anti-mouse IgG
(Vector Laboratories, Burlingame, CA), anti-rat immunoglobulin (Vector Lab-
oratories), anti-rabbit IgG (Vector Laboratories), or anti-goat IgG (Vector
Laboratories) were added 1:200 to 1:500 to sections for 30 min at room
temperature. This was followed by Vectastain ABC Elite reagent (Vector
Laboratories) or alternatively catalyzed signal ampliﬁcation (DakoCytoma-
tion). Peroxidase activity was identiﬁed by reaction with 3,3-diaminobenzi-
dine tetrahydrochloride (Sigma-Aldrich, St. Louis, MO) or 3-amino-9-
ethylcarbazole (Vector Laboratories) substrate. Sections were counterstained
with Mayer’s hematoxylin when appropriate. Staining was quantitated from
digital microscope photographs as percent of positively stained tissue using
ImagePro 6.0 software. For each analysis, 7–10 animals per group were used.
Western blotting. Total lysates from mouse aorta were subjected to 10–12%
SDS-PAGE and transferred onto polyvinylidene diﬂuoride membranes. The
membranes were incubated with mouse monoclonal anti–MCP-1 antibody
(R&D Systems) at 1 g/ml or mouse monoclonal anti–-actin (Abcam) at
1/10,000 dilution. The membranes were washed with Tris-buffered saline with
Tween and then incubated with EnVision	 System–HRP-Labeled Polymer
anti-mouse secondary antibody at 1/25 (DakoCytomation). Immunoreactivity
was detected using an enhanced chemiluminescence kit (Sigma-Aldrich).
Statistical analysis. Data were analyzed by ANOVA using SPSS 15.0 soft-
ware. Post hoc comparisons were made among the various groups using
Fishers least signiﬁcant difference method. Data are expressed as means  SE
unless otherwise speciﬁed. P 
 0.05 was considered to be statistically
signiﬁcant.
RESULTS
Metabolic parameters. The induction of diabetes in both
RAGE
//apoE
/ and apoE
/ mice resulted in in-
creased plasma glucose and GHb concentrations, which
were comparable between the diabetic groups (Table 1).
Plasma concentrations of total and LDL cholesterol levels
were also signiﬁcantly increased in both groups following
the induction of diabetes, although this increase was
attenuated in RAGE
//apoE
/ mice.
Plaque accumulation. The induction of diabetes in
apoE
/ mice led to a signiﬁcant (approximately fourfold)
increase in total atherosclerotic plaque area. However, this
diabetes-associated increase in plaque area was com-
pletely prevented in diabetic RAGE
//apoE
/ mice, with
plaque accumulation not signiﬁcantly different from that
seen in control apoE
/ mice (Fig. 1A). The reduction in
the plaque accumulation in diabetic RAGE
//apoE
/
mice was observed at all three aortic sites: the arch,
thoracic, and abdominal aortas. In addition, there was a
further reduction in plaque area in nondiabetic RAGE
//
apoE
/ mice when compared with control apoE
/ mice
(Fig. 1A and B).
Plaque morphology and smooth muscle cell recruit-
ment. The induction of diabetes was not only associated
with plaque accumulation, but, in addition, diabetic plaque
was also signiﬁcantly more complex, characterized by
TABLE 1
Metabolic parameters of the groups at week 20
Parameters
Control
apoE
/
Diabetic
apoE
/
Control
RAGE
//apoE
/
Diabetic
RAGE
//apoE
/
n 10 10 10 10
GHb (%)* 3.8  0.1 15.8  0.7† 4.5  0.2†‡ 15.0  0.4§
Body weight (g)* 30.7  0.4 24.5  0.6† 38.4  1.1†‡ 27.7  0.5‡§
Plasma glucose (mmol/l) 11.3  0.9 31.2  1.2† 9.6  1.2‡ 31.0  1.9§
Total cholesterol (mmol/l) 14.0  1.1 25.6  2.1† 12.7  0.6‡ 21.1  1.2§
HDL cholesterol (mmol/l) 2.6  0.2 3.1  0.4 3.1  0.2 4.0  0.3§
LDL cholesterol (mmol/l) 10.0  1.0 21.6  1.9† 8.8  0.4‡ 16.5  0.8‡§
Triglycerides (mmol/l) 1.8  0.3 2.1  0.3 1.9  0.4 1.4  0.2
Data are means  SE. *GHb and weight measurements performed in 24 animals/group. †P 
 0.001 vs. control apoE
/ group; ‡P 
 0.05 vs.
diabetic apoE
/ group; §P 
 0.05 vs. control RAGE
//apoE
/.
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and leukocyte recruitment similar to that seen in human
disease. Furthermore, atherosclerotic plaque in diabetic
apoE
/ mice involves the proliferation and migration of
medial vascular smooth muscle cells into the vessel in-
tima, as demonstrated by increased expression of -SMA
protein when compared with control apoE
/ mice (Sup-
plementary Fig. 2). However, the atherosclerotic plaque in
diabetic RAGE
//apoE
/ mice was signiﬁcantly less
complex, with reduced -SMA expression when compared
with diabetic apoE
/ mice.
Vascular accumulation of macrophages and T-cells.
Leukocyte recruitment is a key component of vascular
inﬂammation and atherogenesis. In our study, there was
increased CD3 staining in the vessel wall of the diabetic
apoE
/ mice, consistent with accumulation of T-cells
(Fig. 2A and B). T-cell recruitment associated with diabe-
tes was signiﬁcantly decreased in the RAGE
//apoE
/
mice to levels not signiﬁcantly different from control
apoE
/ mice, with control RAGE
//apoE
/ mice show-
ing an additional reduction in vascular T-cell recruitment.
Similarly, macrophage accumulation, as detected by stain-
ing with the F4/80 marker, was signiﬁcantly increased in
diabetic apoE
/ mice compared with controls (Fig. 2C
and D). Macrophage accumulation was also reduced in the
diabetic RAGE
//apoE
/ mice when compared with
diabetic apoE
/ mice. Macrophage staining was detected
in both the vascular wall and the ﬁbrous cap of the
atherosclerotic lesions, particularly in diabetic apoE
/
mice.
Markers of vascular inﬂammation. To explore the
potential mechanisms responsible for vascular protection
in our model, we studied the aortic gene transcription of
various proteins that have previously been linked to
generation of vascular lesions (9,18,19). In particular,
vascular inﬂammation is thought to be the key initiator of
atherosclerosis in both experimental and human disease.
Accelerated atherosclerosis in diabetic apoE
/ mice was
associated with increased aortic expression of the proin-
ﬂammatory transcription factor NF-B subunit p65,
MCP-1, VCAM-1, tissue factor, and the renin-angiotensin
system (RAS)-related C3 botulinum substrate 1 (rac1)
(Table 2). Reduction in plaque area in RAGE
//apoE
/
mice was also associated with a signiﬁcant reduction in
gene expression of these proatherosclerotic mediators to
levels similar to those observed in control apoE
/ aortas
(Table 2). By immunohistochemistry, MCP-1 expression
was increased at least twofold in diabetic apoE
/ mice
particularly within the plaque, speciﬁcally foam cells and
macrophages, and this increase was not seen in the aortas
from diabetic RAGE
//apoE
/ mice (Supplementary
Fig. 3A and B). In addition, Western blot analysis showed
that MCP-1 protein expression was increased twofold in
aortic extracts from diabetic apoE
/ mice, and this
increased expression was signiﬁcantly reduced in the
aortas from diabetic RAGE
//apoE
/ (Supplementary
Fig. 3C). Aortic VCAM-1 protein expression was also
assessed by immunohistochemistry. Diabetic apoE
/
mice had signiﬁcantly increased vascular VCAM-1 staining,
including within endothelial cells, and this was not seen in
control apoE
/ mice or diabetic and control RAGE
//
apoE
/ mice (Supplementary Fig. 4).
Expression of collagens and matrix metalloprotein-
ases. Gene expression of collagen I, III, IV ( I), and IV
III were increased in the diabetic apoE
/ aorta compared
with the control apoE
/ aorta (Table 2). Collagen III gene
expression was signiﬁcantly decreased in the diabetic
RAGE
//apoE
/ aorta when compared with diabetic
apoE
/ mice. We also assessed collagen protein expres-
sion in the vascular wall by immunohistochemistry, spe-
ciﬁcally assessing the ﬁbrillar type III collagen and the
basement membrane type IV collagen. Diabetic apoE
/
mice have signiﬁcantly increased vascular collagen III and
collagen IV deposition compared with control apoE
/
mice (Supplementary Figs. 5 and 6). The diabetic RAGE
//
apoE
/ mice had signiﬁcantly less collagen III and IV
staining.
We also examined the gene expression of matrix metal-
loproteinases 2 and 9 (MMP-2 and MMP-9, respectively)
that are involved in the inﬂammatory response and in
FIG. 1. A: Quantitation of atherosclerotic plaque area (%) of aortic
segments by the en face method in total aorta (a), aortic arch (b),
thoracic aorta (c), and abdominal aorta (d). *P < 0.01 vs. control
apoE
/,† P < 0.01 vs. diabetic apoE
/,‡ P < 0.05 vs. control RAGE
//
apoE
/. B: Representative photomicrographs of aortas from con-
trol apoE
/ (a), diabetic apoE
/ (b), control RAGE
//apoE
/ (c),
and diabetic RAGE
//apoE
/ (d) using the en face technique. Lesions
are shown in red after Sudan IV staining. (Please see http://dx.doi.org/
10.2337/db07-1808 for a high-quality digital representation of this
ﬁgure.)
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in the expression of MMP-2 and a twofold induction in the
expression of MMP-9 in the diabetic apoE
/ aorta com-
pared with the control apoE
/ aorta. MMP-9 gene expres-
sion was signiﬁcantly attenuated in diabetic RAGE
//
apoE
/ aorta, whereas MMP-2 gene expression was
similar to that seen in diabetic apoE
/ aorta.
Accumulation of RAGE ligands. The accumulation of a
range of RAGE ligands, including the advanced glycation
end product (AGE), CML, HMGB1, and S100A8/A9, in
settings such as diabetes are considered to play a role in
progressive vascular injury. As expected, diabetic apoE
/
mice had a signiﬁcant elevation in vascular AGE deposi-
tion when compared with the nondiabetic apoE
/ ani-
mals, as detected by immunostaining for the well-
described AGE, CML (Fig. 3). CML immunostaining was
reduced in the aortas of diabetic RAGE
//apoE
/ mice
to levels not signiﬁcantly different from control animals. A
similar pattern was seen with respect to another RAGE
ligand, HMGB1 (1), with increased expression in diabetic
apoE
/ aorta when compared with the control apoE
/
mice, with normalization in RAGE
//apoE
/ mice (Fig.
4). We also measured plasma HMGB1 concentrations.
Interestingly, plasma HMGB1 levels were higher in dia-
betic RAGE
//apoE
/ mice compared with diabetic
apoE
/ mice (369  44 vs. 201  13 ng/ml, P 
 0.05).
Nondiabetic RAGE
//apoE
/ mice tended to have
slightly higher circulating HMGB1 levels than nondiabetic
apoE
/ mice (356  63 vs. 235  28 ng/ml, P  0.11).
The diabetic apoE
/ mice had signiﬁcantly increased
positive staining of the proinﬂammatory cytokine, S100A8/
A9, a known RAGE ligand (21) when compared with
control animals (Fig. 5A and B), with prominent staining
appearing in the aortic lesions, particularly within macro-
phages, foam cells, and endothelial cells. In the RAGE
//
apoE
/ mice, the aortic expression of S100A8/A9 protein
was signiﬁcantly decreased when compared with diabetic
apoE
/ aortas. The diabetic apoE
/ mice also had a
signiﬁcant elevation in circulating levels of S100A8/A9
when compared with control animals (Fig. 5C). In the
FIG. 2. A: Representative aortic sections showing anti-CD3 staining demonstrating T-cell accumulation in control apoE
/ (a), diabetic apoE
/
(b), control RAGE
//apoE
/ (c), and diabetic RAGE
//apoE
/ (d) mice. Scale bar  20 m. B: Graph presenting percentage of CD3-positive
staining in each group. *P < 0.05 vs. control apoE
/,† P < 0.001 vs. diabetic apoE
/,‡ P < 0.05 vs. control RAGE
//apoE
/.§ P < 0.001 vs.
control apoE
/. Data are means  SE. C: Representative aortic sections of F4/80 staining demonstrating macrophage inﬁltration in control
apoE
/ (a), diabetic apoE
/ (b), control RAGE
//apoE
/ mice (c), and diabetic RAGE
//apoE
/ (d). Scale bar  20 m. D: Graph presenting
percentage of F4/80-positive staining in each group. *P < 0.001 vs. control apoE
/,† P < 0.01 vs. diabetic apoE
/,‡ P < 0.05 vs. control
RAGE
//apoE
/. Data are means  SE. (Please see http://dx.doi.org/10.2337/db07-1808 for a high-quality digital representation of this ﬁgure.)
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//apoE
/ mice, S100A8/A9 levels were similar to
those seen in control mice.
Expression of AGE receptors. As previously described
(14,15), the expression of full-length RAGE in apoE
/
mice was signiﬁcantly increased after the induction of
diabetes (Table 2), with focal expression overlying athero-
sclerotic plaque (data not shown). There was no RAGE
expression in RAGE
//apoE
/ aorta. The induction of
diabetes was also associated with increased expression of
AGE clearance receptors, including AGE-R1 (oligosac-
charyl transferase-48), AGE-R3 (galectin-3), and the type B
macrophage scavenger receptor, CD36. However, in
RAGE
//apoE
/ mice, the increased gene expression of
these other AGE receptors was signiﬁcantly attenuated
(Table 2).
NADPH oxidase and oxidative stress in the vascular
wall. We determined the potential impact of RAGE on the
superoxide-generating NADPH oxidase in the diabetic
vasculature. Interestingly, diabetes induced a 5.3-fold in-
crease in expression of NADPH oxidase subunit p47phox
and a 3.5-fold increase in gp91phox expression in the
apoE
/ aorta, whereas in diabetic RAGE
//apoE
/
double knockout mice, this upregulation of NADPH oxi-
dase subunits was attenuated (Table 2). Diabetic apoE
/
mice also had increased expression of nitrotyrosine in
their aortas, suggesting increased peroxynitrite-mediated
protein oxidation (Fig. 6). Diabetes did not lead to a
similar increase in nitrotyrosine staining in the RAGE
//
apoE
/ mice.
AT1 receptor expression. Reﬂecting an activated vascu-
lar RAS, which is known to upregulate NADPH-oxidase–
dependent reactive oxygen species (ROS) generation (22),
diabetic apoE
/ mice had a marked increase in gene
expression of the angiotensin II type 1a receptor (AT1a).
Aortic AT1a gene expression was signiﬁcantly reduced in
diabetic RAGE
//apoE
/ mice when compared with
diabetic apoE
/ mice (Table 2).
DISCUSSION
Atherosclerotic vascular disease is a major cause of mor-
bidity and mortality in the diabetic population with accel-
erated plaque accumulation and vascular inﬂammation.
Although a number of mechanisms have been postulated
to contribute to the development and progression of
atherosclerotic disease in diabetes, in the present study,
we provide evidence that RAGE-dependent pathways play
a central role in promoting vascular lesions in a rodent
model of advanced atherosclerosis, the diabetic apoE
/
mouse. Our results show for the ﬁrst time that the absence
of RAGE suppresses diabetes-accelerated atherosclerosis.
Our group has previously shown that the atherosclerotic
plaques seen in diabetic apoE
/ mice resemble the
complex morphology seen in patients with diabetes, in-
cluding enhanced accumulation of macrophages, foam
cells, and cholesterol clefts within the fatty atheroma and
increased expression of inﬂammatory markers, proinﬂam-
matory cytokines, and chemokines (14,15,18). Without
normalizing glucose or lipid levels, we show that in the
absence of both full-length and sRAGE expression in
diabetic RAGE
//apoE
/ double knockout mice, the
extent of plaque accumulation, vascular inﬂammation, and
oxidative stress was signiﬁcantly reduced to levels similar
to those observed in control apoE
/ mice. In addition,
atherosclerosis was further reduced in control RAGE
//
apoE
/ mice. These data are consistent with previous
studies in nondiabetic RAGE
/ mice. RAGE
/ mice
demonstrated suppression of neointimal expansion after
TABLE 2
Gene expression of proatherogenic mediators in the aorta
Parameters
Control
apoE
/
Diabetic
apoE
/
Control
RAGE
//apoE
/
Diabetic
RAGE
//apoE
/
n 12 10 14 14
Inﬂammatory mediators
p65 1.0  0.1 2.6  0.5* 1.0  0.1† 1.5  0.2*†
VCAM-1 1.0  0.2 4.2  0.6* 1.7  0.2*† 1.6  0.4†
MCP-1 1.0  0.2 6.2  1.3* 1.7  0.4*† 2.6  0.7*†
Tissue factor 1.0  0.2 2.9  0.7* 0.6  0.3† 1.7  0.4‡
NADPH oxidase and RAS
p47phox 1.0  0.2 5.1  0.7* 1.0  0.2† 1.8  0.3*†‡
gp91phox 1.0  0.3 3.54  0.5* 1.22  0.3† 2.1  0.3*†‡
rac1 1.0  0.1 1.5  0.2* 1.4  0.1 1.3  0.2†
AT1a 1.0  0.2 5.3  1.3* 1.2  0.3† 1.4  0.3†
AGE receptors
RAGE 1.0  0.1 4.4  1.1* 0 0
AGE-R1 1.0  0.1 2.4  0.3* 1.1  0.1† 1.4  0.2†
AGE-R2 1.0  0.1 2.1  0.4* 1.2  0.1 1.7  0.2
AGE-R3 1.0  0.3 4.6  1.1* 0.9  0.1 1.8  0.3†
CD36 1.0  0.5 2.1  0.4* 0.8  0.1† 1.0  0.2†
Indicators of matrix accumulation
and degradation
Collagen I 1.0  0.1 4.1  1.1* 1.2  0.1† 3.1  0.6*‡
Collagen III 1.0  0.2 8.9  2.9* 1.7  0.2*† 2.8  0.6*†
Collagen IV (I) 1.0  0.1 2.9  0.7* 1.6  0.2*† 2.7  0.6*
Collagen IV (III) 1.0  0.1 3.7  1.2* 3.0  0.7* 2.3  0.4*
MMP-2 1.0  0.2 3.0  0.6* 1.2  0.3† 2.1  0.6
MMP-9 1.0  0.2 1.9  0.4* 1.1  0.3 0.8  0.2†
Data are means  SE. *P 
 0.05 vs. control apoE
/ group; †P 
 0.05 vs. diabetic apoE
/ group; ‡P 
 0.05 vs. control RAGE
//apoE
/.
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study in apoE/RAGE double knockout mice has also
demonstrated reduced plaque area, albeit in a nondiabetic
context (23).
RAGE is pattern recognition receptor (1) that is able to
bind a chemically diverse range of AGEs and other non-
AGE ligands, including s100/calgranulins, HMGB1, and
-sheet ﬁbrils. In atherosclerotic vascular disease, the
expression of RAGE is focally increased (14,15,21), paral-
leling an accumulation in RAGE ligands. The major RAGE
ligand in the context of diabetes remains to be established.
However, the efﬁcacy of AGE-reducing interventions, in-
cluding alagebrium and aminoguanidine, on diabetes-asso-
ciated atherosclerosis suggests that AGEs play a pivotal
role (14). In this study, we demonstrate increased vascular
accumulation of CML along with other RAGE ligands in
diabetic apoE
/ mice. This increase in vascular CML was
markedly attenuated in diabetic RAGE
//apoE
/ mice,
although the hyperglycemia and hyperlipidemia were not
corrected. This decrease in vascular AGEs was not due to
overexpression of AGE clearance receptors in RAGE
//
apoE
/ mice. In fact, diabetes-associated increases in
AGE-R1 (OST-3) and AGE-R3 (galactin-3) were signiﬁ-
cantly attenuated in diabetic RAGE
//apoE
/ mice,
possibly reﬂecting reduced AGE accumulation in these
animals. Expression of the type B macrophage scavenger
receptor CD36 (24) was also attenuated in diabetic
RAGE
//apoE
/ mice. Although this change is likely to
be secondary to reduced leukocyte recruitment, CD36 has
been clearly demonstrated to play a proatherogenic role
because the absence of macrophage CD36 protects against
vascular lesion formation in mice (25). Thus, one cannot
exclude that some of the antiatherosclerotic effects seen
with RAGE deletion could be related to changes in the
expression of CD36.
Plaque accumulation in the diabetic apoE
/ mouse is
closely correlated with the generation of ROS, which drive
a number of proatherogenic processes, such as monocyte
inﬁltration, smooth muscle cell recruitment, cell adhesion,
and increased accumulation of AGEs, which are all ob-
served in the diabetic apoE
/ plaque. For example, we
FIG. 3. A: Representative aortic sections demonstrating increased CML
staining in the diabetic apoE
/ aorta. Panel presents aorta from
control apoE
/ (a), diabetic apoE
/ (b), control RAGE
//apoE
/
(c), and diabetic RAGE
//apoE
/ (d) mice. Scale bar  20 m. B:
Graph presenting percentage of CML-positive aortic area in each
group. *P < 0.001 vs. control apoE
/,† P < 0.01 vs. diabetic apoE
/,
‡P < 0.05 vs. diabetic apoE
/. Data are means  SE. (Please see
http://dx.doi.org/10.2337/db07-1808 for a high-quality digital represen-
tation of this ﬁgure.)
FIG. 4. A: Representative aortic sections demonstrating HMGB1 stain-
ing in control apoE
/ (a), diabetic apoE
/ (b), control RAGE
//
apoE
/ (c), and diabetic RAGE
//apoE
/ (d) mice. Scale bar  20
m. B: Graph presenting percentage of HMGB1-positive aortic area in
each group. *P < 0.05 vs. control apoE
/,† P < 0.05 vs. diabetic
apoE
/. Data are expressed as means  SE. (Please see http://
dx.doi.org/10.2337/db07-1808 for a high-quality digital representation
of this ﬁgure.)
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GPx1
//apoE
/ mice accelerates diabetes-associated
atherosclerosis via upregulation of proinﬂammatory and
proﬁbrotic pathways (26). The role of RAGE as a mediator
of oxidative stress in diabetes was also observed in the
present study. In our study, diabetes was associated with
increases in vascular oxidative stress, as demonstrated by
aortic nitrotyrosine staining. This probably occurred
partly as a result of increased expression of p47phox and
gp91phox, subunits of NAPDH oxidase, and rac1, a GT-
Pase involved in NADPH oxidase activation. Expression of
the NADPH subunits as well as nitrotyrosine staining were
signiﬁcantly attenuated in diabetic RAGE
//apoE
/
mice. Furthermore, aortic gene expression of the AT1a
receptor, which is known to enhance ROS generation via
NADPH oxidase (27), was increased in diabetic apoE
/
mice yet was signiﬁcantly reduced in the diabetic RAGE
//
apoE
/ mice.
RAGE activation is involved not only in the acceleration
of atherosclerotic lesion formation but also in promoting
proinﬂammatory pathways considered to play an impor-
tant role in diabetes-accelerated atherosclerosis. For ex-
ample, the diabetic plaque is characterized by the
increased expression of inﬂammatory cytokines, chemo-
kines and adhesion molecules that promote leukocyte
inﬁltration and foam cell accumulation. This inﬂammatory
response was clearly attenuated in the diabetic RAGE
//
apoE
/ mice, as reﬂected by decreased accumulation of
macrophages and T-cells and reduced aortic expression of
related chemokines, cytokines, and adhesion molecules. A
number of different components contribute to RAGE-
induced inﬂammation, including oxidative stress and AGE
accumulation. However, one key mediator appears to be
activation of the proinﬂammatory transcription factor
NF-B, because RAGE has the unique ability to sustain
NF-B activation through de novo synthesis of NF-B
p65-mRNA and to provide a constantly growing pool of
transcriptional active NF-B (28). The downstream effects
of this pathway include activation of NADPH oxidase,
VCAM-1, and tissue factor and the autoinduction of RAGE
expression in a positive feedback loop (29). In our study,
the expression of the NF-B subunit p65 was upregulated
in the diabetic apoE
/ aorta. By contrast, diabetes-
associated upregulation of NF-B and subsequent NF-B–
dependent expression of proinﬂammatory genes were
FIG. 5. A: Representative histological sections demonstrating in-
creased S100A8/A9 staining, particularly in foam cells, endothelial
cells (see arrow) and macrophages (see double arrow) in the diabetic
apoE
/ aorta. Panel presents photomicrographs from aortic wall and
plaques in control apoE
/ (a), diabetic apoE
/ (b), control RAGE
//
apoE
/ (c), and diabetic RAGE
//apoE
/ (d) mice. Scale bar  20
m. B: Graph presenting percentage of S100A8/A9-positive aortic area
in each group. *P < 0.05 vs. control apoE
/,† P < 0.01 vs. diabetic
apoE
/. C: Plasma levels of S100A8/A9 are increased in diabetic
apoE
/ mice compared with control apoE
/ and RAGE
//apoE
/.
*P < 0.01 vs. control apoE
/,† P < 0.001 vs. diabetic apoE
/. Data are
means  SE. (Please see http://dx.doi.org/10.2337/db07-1808 for a
high-quality digital representation of this ﬁgure.)
FIG. 6. A: Nitrotyrosine expression is enhanced in diabetic apoE
/
aorta indicative of increased oxidative stress. Representative aortic
sections showing nitrotyrosine staining in control apoE
/ (a), dia-
betic apoE
/ (b), control RAGE
//apoE
/ (c), and diabetic RAGE
//
apoE
/ (d) mice. Scale bar  20 m. B: Graph presenting percentage
of nitrotyrosine-positive aortic area in each group. *P < 0.05 vs.
control apoE
/,† P < 0.05 vs. diabetic apoE
/. Data are means  SE.
(Please see http://dx.doi.org/10.2337/db07-1808 for a high-quality digi-
tal representation of this ﬁgure.)
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//apoE
/ mice. To com-
plement the ﬁnding with respect to NF-B, we measured
gene expression of the NF-B–dependent protein, MCP-1.
MCP-1 gene expression was increased at least sixfold in
the diabetic apoE
/ mice, and this increase was signiﬁ-
cantly attenuated in the RAGE
//apoE
/ mice in asso-
ciation with reduced macrophage inﬁltration.
In the present study, increased gene expression of
various collagens was observed in diabetic apoE
/ mice.
This result complements previous ﬁndings by several
groups, including our own by demonstrating increased
matrix accumulation as assessed by picrosirius red or
increased collagen protein expression as assessed immu-
nohistochemically (9,14). RAGE deletion in these diabetic
apoE
/ mice particularly inﬂuenced collagen III gene
expression, a ﬁnding similar to that seen previously with
two chemically disparate AGE inhibitors (14). With re-
spect to MMP-9 expression, the increase in mRNA levels
in these diabetic apoE
/ mice complements ﬁndings by
another group that speciﬁcally examined MMP-9 expres-
sion and activity (9). Furthermore, the decrease in MMP-9
expression seen in the diabetic RAGE
//apoE
/ mice is
similar to that seen previously in studies using sRAGE (9).
Previously, it has been suggested that the changes ob-
served with respect to matrix and MMP expression in
response to inhibition of RAGE may reﬂect stabilization of
the plaque. Nevertheless, the long-term implications of the
changes in MMPs and collagens seen in this model remain
controversial because this is not considered a model of
plaque rupture.
The clear vasculoprotection observed in the diabetic
RAGE
//apoE
/ mice further support previous experi-
mental studies showing that blockade of RAGE activation,
either with neutralizing antibodies or sRAGE (8,9,12),
prevents the initiation and progression of atheroma for-
mation in diabetic mice. It is noteworthy that in our study,
both full-length and truncated isoforms of RAGE were
absent in RAGE
//apoE
/ mice. Because RAGE has
been reported to not only bind to AGEs but also to other
ligands such as HMGB1 and certain S100 isoforms, these
ligands were examined in this study. S100 A8/9 levels were
increased in the plasma and aortic tissues in diabetic
apoE
/ mice, and this increase was not observed in the
RAGE
//apoE
/ double knockout mice, even in the
presence of concomitant diabetes. A similar upregulation
of HMGB1 in the aorta of diabetic mice was also not seen
in vessels from RAGE
//apoE
/ mice. However, the
circulating levels of HMGB1 were higher in the double
knockout mice. This ﬁnding is unexplained but may occur
because RAGE
//apoE
/ mice have no sRAGE to bind
HMBG from the circulation, thus enhancing accumulation
of this protein within the plasma. These ﬁndings extend
recent in vitro studies, albeit in a nondiabetic context,
describing effects of various RAGE ligands on chemo-
kines, adhesion molecules, and MMPs, including MCP-1,
VCAM-1, and MMP-2 (23).
The ﬁnding that atherosclerosis was attenuated even in
the absence of potentially protective circulating sRAGE
strongly supports the postulate that the major mechanism
of action of sRAGE is local antagonism of RAGE-depen-
dent signaling. The importance of the full-length RAGE
receptor in inﬂammatory vascular injury, even in the
nondiabetic context, is suggested by the ﬁnding that even
in control RAGE
//apoE
/ mice, there was reduced
plaque accumulation, as was recently reported by another
group (23).
In summary, this study demonstrates that accelerated
atherosclerotic plaque accumulation associated with dia-
betes is prevented in the absence of RAGE. The antiath-
erosclerotic effects seen in diabetic RAGE
//apoE
/
mice were associated with reduced expression of a range
of proatherogenic factors, including ROS and inﬂamma-
tory cytokines, ultimately leading to reduced leukocyte
recruitment. Thus, these data provide further support for
the development of novel therapies that target RAGE
activation in the prevention and treatment of diabetic
macrovascular complications.
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